IRON DISC MEDICINE INC

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th at 3:00 pm PT / 6:00 pm ET.

A live webcast of the presentation will be available through the investor relations section of the Company's website at and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .

Media Contact

Peg Rusconi

Deerfield Group

Investor Relations Contact

Christina Tartaglia

Precision AQ



EN
07/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Con...

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th at 3:00 pm PT / 6:00 pm ET. A live webcast of ...

 PRESS RELEASE

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Tri...

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments ...

 PRESS RELEASE

Disc Medicine Reports Third Quarter 2025 Financial Results and Provide...

Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner’s National Priority Voucher (CNPV), which is designed to shorten the expected NDA review period to 1-2 months from NDA acceptanceAcceleration of ongoing efforts to support the potential earlier approval and commercialization of bitopertin for EPP in the US, expected in late 2025 or early 2026Initial data from Phase 2 study of DISC-0974 in...

 PRESS RELEASE

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Pha...

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced two poster presentations, including initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF, at the ...

 PRESS RELEASE

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10th at 4:30 p.m. ET.Stifel 2025 Healthcare Conference on Thursday, No...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch